PRESS RELEASE

23rd July 2013

A new player in brain disease and stroke

Research that shows how cells respond to brain damage may lead to a new treatment for stroke and neurodegenerative diseases.

In degenerative brain diseases and after stroke, nerve cells die while their support cells activate the brain’s immune system to cause further damage. Now Adrian Pini, Jonathan Gilthorpe and Andrew Lumsden at the MRC Centre for Developmental Neurobiology at King’s College London, have found that a single protein, histone H1, causes these distinct outcomes.

The research passed peer review within a week of being published in F1000Research, where Jan-Marino Ramirez, of the University of Washington, called the work “a very important contribution to our understanding of neurodegenerative disease and the response of the brain to injury” in his public referee report. He also noted that he is “confident that this study will be a much cited contribution to the field of traumatic brain injury”.

The most unexpected finding in this study is that a histone protein is responsible for neuronal damage. “Histone H1 partners with DNA in the cell nucleus and has been thought of as harmless,” explain the authors, “The surprise came when we discovered that it can be released from brain cells upon injury, killing healthy nerve cells and activating the damaging immune response”.

The research team is now working on ways to suppress these harmful actions, which may lead to the development of new treatments for neurodegenerative disease and stroke.

To find out more about F1000Research, please contact Eleanor Howell on +44 (0)20 7631 9129 or email press@f1000.com. For more information, visit http://f1000research.com/.

********************

Read the full article and referee reports:

About F1000Research
F1000Research is an original open access journal for life scientists that offers immediate publication, transparent peer review (post-publication) and full data deposition and sharing. The journal accepts all scientifically sound articles, including single findings, case reports, protocols, replications, null/negative results and more traditional articles. F1000Research is published by U.K.-based Faculty of 1000 (F1000) and has offices in London and New York.